Avalo Deferred Long Term Liab vs Total Assets Analysis

AVTX Stock  USD 9.23  0.12  1.32%   
Avalo Therapeutics financial indicator trend analysis is way more than just evaluating Avalo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avalo Therapeutics is a good investment. Please check the relationship between Avalo Therapeutics Deferred Long Term Liab and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avalo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Deferred Long Term Liab vs Total Assets

Deferred Long Term Liab vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avalo Therapeutics Deferred Long Term Liab account and Total Assets. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Avalo Therapeutics' Deferred Long Term Liab and Total Assets is -0.06. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Total Assets in the same time period over historical financial statements of Avalo Therapeutics, assuming nothing else is changed. The correlation between historical values of Avalo Therapeutics' Deferred Long Term Liab and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Avalo Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Deferred Long Term Liab i.e., Avalo Therapeutics' Deferred Long Term Liab and Total Assets go up and down completely randomly.

Correlation Coefficient

-0.06
Relationship DirectionNegative 
Relationship StrengthInsignificant

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Total Assets

Total assets refers to the total amount of Avalo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Avalo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Avalo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avalo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avalo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.At this time, Avalo Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 32.5 K in 2024, whereas Discontinued Operations is likely to drop (32.6 K) in 2024.
 2021 2022 2023 2024 (projected)
Interest Expense2.4M4.2M3.4M5.6M
Depreciation And Amortization1.7M166K158K150.1K

Avalo Therapeutics fundamental ratios Correlations

0.90.850.780.61-0.27-0.480.450.660.82-0.090.68-0.070.190.540.560.570.810.210.610.63-0.30.830.540.480.31
0.90.960.640.580.04-0.360.580.440.89-0.10.47-0.230.180.540.420.650.640.180.580.48-0.130.910.660.610.3
0.850.960.550.590.08-0.370.610.480.8-0.170.5-0.320.220.490.40.690.650.10.630.440.120.840.60.60.22
0.780.640.550.41-0.38-0.350.150.380.71-0.350.43-0.05-0.430.470.47-0.040.570.40.160.46-0.460.660.380.210.33
0.610.580.590.41-0.27-0.870.570.590.35-0.010.630.280.150.530.850.430.64-0.190.380.5-0.010.33-0.120.04-0.16
-0.270.040.08-0.38-0.270.18-0.18-0.70.2-0.25-0.69-0.05-0.02-0.52-0.220.07-0.620.09-0.07-0.770.420.130.390.42-0.42
-0.48-0.36-0.37-0.35-0.870.18-0.15-0.38-0.320.22-0.38-0.65-0.02-0.39-0.99-0.19-0.370.15-0.15-0.240.01-0.10.13-0.10.52
0.450.580.610.150.57-0.18-0.150.550.190.450.58-0.480.350.540.130.610.63-0.060.640.650.170.41-0.05-0.070.42
0.660.440.480.380.59-0.7-0.380.550.130.310.99-0.140.480.470.40.570.95-0.140.670.87-0.070.3-0.050.010.35
0.820.890.80.710.350.2-0.320.190.13-0.330.15-0.03-0.050.350.40.390.360.410.370.2-0.260.880.810.70.13
-0.09-0.1-0.17-0.35-0.01-0.250.220.450.31-0.330.29-0.120.570.02-0.260.350.21-0.160.440.39-0.09-0.13-0.24-0.220.3
0.680.470.50.430.63-0.69-0.380.580.990.150.29-0.160.440.460.40.550.97-0.160.650.85-0.110.35-0.07-0.020.39
-0.07-0.23-0.32-0.050.28-0.05-0.65-0.48-0.14-0.03-0.12-0.16-0.05-0.030.63-0.22-0.23-0.19-0.35-0.23-0.28-0.34-0.23-0.01-0.68
0.190.180.22-0.430.15-0.02-0.020.350.48-0.050.570.44-0.05-0.03-0.050.850.38-0.290.650.30.170.10.10.240.08
0.540.540.490.470.53-0.52-0.390.540.470.350.020.46-0.03-0.030.430.240.53-0.080.110.74-0.270.290.040.060.36
0.560.420.40.470.85-0.22-0.990.130.40.4-0.260.40.63-0.050.430.160.41-0.090.140.28-0.090.17-0.070.13-0.45
0.570.650.69-0.040.430.07-0.190.610.570.390.350.55-0.220.850.240.160.6-0.150.810.450.170.530.390.480.19
0.810.640.650.570.64-0.62-0.370.630.950.360.210.97-0.230.380.530.410.6-0.030.690.87-0.180.550.120.110.47
0.210.180.10.4-0.190.090.15-0.06-0.140.41-0.16-0.16-0.19-0.29-0.08-0.09-0.15-0.030.240.01-0.140.220.26-0.080.06
0.610.580.630.160.38-0.07-0.150.640.670.370.440.65-0.350.650.110.140.810.690.240.540.220.490.30.260.2
0.630.480.440.460.5-0.77-0.240.650.870.20.390.85-0.230.30.740.280.450.870.010.54-0.320.33-0.03-0.070.59
-0.3-0.130.12-0.46-0.010.420.010.17-0.07-0.26-0.09-0.11-0.280.17-0.27-0.090.17-0.18-0.140.22-0.32-0.28-0.150.0-0.46
0.830.910.840.660.330.13-0.10.410.30.88-0.130.35-0.340.10.290.170.530.550.220.490.33-0.280.770.640.46
0.540.660.60.38-0.120.390.13-0.05-0.050.81-0.24-0.07-0.230.10.04-0.070.390.120.260.3-0.03-0.150.770.910.23
0.480.610.60.210.040.42-0.1-0.070.010.7-0.22-0.02-0.010.240.060.130.480.11-0.080.26-0.070.00.640.91-0.01
0.310.30.220.33-0.16-0.420.520.420.350.130.30.39-0.680.080.36-0.450.190.470.060.20.59-0.460.460.23-0.01
Click cells to compare fundamentals

Avalo Therapeutics Account Relationship Matchups

Avalo Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets36.1M43.8M80.2M33.4M21.0M37.3M
Other Current Liab10.1M12.2M16.0M12.7M3.6M3.5M
Total Current Liabilities12.2M15.2M19.9M22.1M4.6M4.4M
Total Stockholder Equity21.0M24.6M23.1M(10.9M)7.3M8.3M
Property Plant And Equipment Net1.4M1.6M2.7M2.4M2.0M1.1M
Net Debt(2.3M)(18.5M)(21.8M)6.2M(6.9M)(7.2M)
Retained Earnings(114.3M)(177.8M)(262.2M)(303.8M)(335.1M)(318.4M)
Accounts Payable2.1M2.6M3.4M2.9M446K423.7K
Cash3.6M18.9M54.6M13.2M7.4M7.0M
Non Current Assets Total18.4M17.8M18.4M17.0M12.6M16.6M
Non Currrent Assets Other102K149K1.2M131K117.9K112.0K
Cash And Short Term Investments11.2M18.9M54.6M13.2M7.4M7.0M
Common Stock Shares Outstanding19.8K25.5K36.2K39.2K277.7K291.6K
Liabilities And Stockholders Equity36.1M43.8M80.2M33.4M21.0M37.3M
Non Current Liabilities Total3.0M4.0M37.2M22.2M9.1M12.1M
Other Current Assets707K4.9M2.4M1.3M844K1.4M
Other Stockholder Equity135.2M202.3M285.1M292.9M342.4M359.6M
Total Liab15.1M19.2M57.1M44.3M13.7M13.0M
Total Current Assets17.7M26.0M61.8M16.4M8.4M8.0M
Common Stock44K75K113K9K1K950.0
Short Long Term Debt Total1.3M426.3K32.8M19.4M537K510.2K
Current Deferred Revenue(155.8K)10.9M16.0M88K101.2K96.1K
Short Term Debt155.8K426K485K6.5M537K510.2K
Net Receivables5.2M2.2M4.8M1.9M136K129.2K
Inventory1.1M21K3K38K20K0.0
Other Liab1.8M2.9M4.4M7.0M6.3M5.8M
Net Tangible Assets4.2M8.6M8.6M(25.3M)(22.8M)(21.7M)
Other Assets101.9K148.6K1.2M1.00.90.86
Net Invested Capital21.0M24.6M55.9M8.5M7.3M6.9M
Property Plant And Equipment Gross1.4M1.6M3.0M2.8M2.5M1.9M
Non Current Liabilities Other1.1M3.9M4.3M3.7M3.4M3.3M
Net Working Capital5.6M10.8M42.0M(5.7M)3.8M3.6M
Intangible Assets31.2M2.4M1.6M38K34.2K32.5K
Property Plant Equipment1.4M1.6M2.7M2.4M2.8M1.6M
Capital Stock47.2K76.3K113K9K1K950.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.